Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

Author(s):

A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.

EP: 1.Prevalence and Pathophysiology of Myasthenia Gravis

EP: 2.Unmet Needs in the Management of Myasthenia Gravis

EP: 3.Standards of Care for Myasthenia Gravis

EP: 4.The Role of Monoclonal Antibodies in the Treatment of Myasthenia Gravis

EP: 5.The Fc Receptor and Mechanisms of Efgartigimod

EP: 6.Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis

EP: 7.Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis

Now Viewing

Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

EP: 1.Prevalence and Pathophysiology of Myasthenia Gravis

EP: 2.Unmet Needs in the Management of Myasthenia Gravis

EP: 3.Standards of Care for Myasthenia Gravis

EP: 4.The Role of Monoclonal Antibodies in the Treatment of Myasthenia Gravis

EP: 5.The Fc Receptor and Mechanisms of Efgartigimod

EP: 6.Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis

EP: 7.Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis

EP: 8.Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

EP: 9.Investigational Agents for the Treatment of Myasthenia Gravis

EP: 10.Collaborating With Primary Care Physicians for the Management of Patients With Myasthenia Gravis